Some of the most exciting drug approvals in recent years have been oligonucleotides and RNA-based therapeutics, sparking great excitement with drug developers. Top highlights that came out of 2023 include CRISPR/Vertex securing their first gene-editing oligo approval, Boehringer Ingelheim’s multi-billion-dollar deal with Ribo’s siRNA.
That’s why the 3rd Oligonucleotide CMC & Analytical Development Summit returned to Boston in August 2024 to gather industry heavyweights such as Amgen, Biogen, and Sanofi along with exciting new players who joined the meeting for the first time like Ionis Pharmaceuticals and OliX Therapeutics.
Across the three days delegates gained access to exclusive opportunities to network with a highly senior, technical crowd composed of CXOs, VPs, Directors, and Heads of QC, AD, and CMC focused on oligonucleotide drug development.
This summit, returning for it's 4th year in 2025 is your perfect opportunity to assess the field, take back actionable insights to your team, and realize the potential of oligonucleotide therapeutics for prevalent diseases and improved market acceptance.
Highlights Included
Ionis Pharmaceuticals explored their process development strategy for a groundbreaking and first-in-class GalNAc-conjugated siRNA and process associated impurities for cost effective manufacturing and scale-up
Exploring the new raw material standards for mRNA production with Sanofi to ensure thorough risk mitigation and improved supply chain management for flawless execution of your processes and manufacturing
QurAlis offered their perspective for CNS-targeting to share unique lessons learned to balance equipment complexity in novel oligos to ensure unity between analytical and CMC teams for robust data and regulatory compliance packages
Biogen dove into novel oligo-conjugates in a tailored workshop to answer your unique analytical and validation questions to accelerate development timeline
Accelerated development of novel formulations, exploration of stability assessments, and optimization of excipient selection with Amgen to bolster next-generation delivery methods, enhance therapeutics potential, and ensure product quality
Companies on the 2024 Program
